Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The Global Burden of Multidrug-Resistant Tuberculosis: An In-Depth Review of Catastrophic Costs, Patient Burdens, and Strategies for Sustainable Healthcare Solutions

View through CrossRef
Background: Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health challenge, with approximately 500,000 new cases reported in 2020, predominantly among vulnerable populations in low- and middle-income countries. The World Health Organization (WHO) aims to mitigate catastrophic costs associated with TB treatment, which often exceed 20% of a household's annual income, leading families into severe financial distress. This systematic review and meta-analysis aimed to assess the global burden of catastrophic expenditures related to MDR-TB, focusing on patient and family financial impacts. Methods: A comprehensive literature search was conducted across five databases (CINAHL, MEDLINE, Embase, Scopus, and Web of Science) and grey literature sources, utilizing relevant keywords related to MDR-TB and cost implications. Studies were selected based on their relevance to catastrophic costs incurred by MDR-TB patients. Results: The analysis revealed that the financial burden for MDR-TB patients is significantly higher than for drug-susceptible TB (DS-TB) cases, with treatment costs ranging from $2,423 in Peru to $14,657 in Tomsk, Russia. Factors influencing these costs include sociodemographic characteristics, diagnostic delays, and the duration of hospitalization. Notably, 43% of TB patients experienced catastrophic expenditures, with MDR-TB patients facing an even greater risk due to longer treatment durations and higher medication costs. Conclusions: In conclusion, the findings underscore the urgent need for effective interventions to reduce the financial burden of MDR-TB on patients and families. Enhanced drug susceptibility testing and improved healthcare access are critical for managing MDR-TB and preventing further economic devastation. Addressing these issues will be vital for achieving the WHO's end-TB strategy and ensuring sustainable healthcare solutions
Title: The Global Burden of Multidrug-Resistant Tuberculosis: An In-Depth Review of Catastrophic Costs, Patient Burdens, and Strategies for Sustainable Healthcare Solutions
Description:
Background: Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health challenge, with approximately 500,000 new cases reported in 2020, predominantly among vulnerable populations in low- and middle-income countries.
The World Health Organization (WHO) aims to mitigate catastrophic costs associated with TB treatment, which often exceed 20% of a household's annual income, leading families into severe financial distress.
This systematic review and meta-analysis aimed to assess the global burden of catastrophic expenditures related to MDR-TB, focusing on patient and family financial impacts.
Methods: A comprehensive literature search was conducted across five databases (CINAHL, MEDLINE, Embase, Scopus, and Web of Science) and grey literature sources, utilizing relevant keywords related to MDR-TB and cost implications.
Studies were selected based on their relevance to catastrophic costs incurred by MDR-TB patients.
Results: The analysis revealed that the financial burden for MDR-TB patients is significantly higher than for drug-susceptible TB (DS-TB) cases, with treatment costs ranging from $2,423 in Peru to $14,657 in Tomsk, Russia.
Factors influencing these costs include sociodemographic characteristics, diagnostic delays, and the duration of hospitalization.
Notably, 43% of TB patients experienced catastrophic expenditures, with MDR-TB patients facing an even greater risk due to longer treatment durations and higher medication costs.
Conclusions: In conclusion, the findings underscore the urgent need for effective interventions to reduce the financial burden of MDR-TB on patients and families.
Enhanced drug susceptibility testing and improved healthcare access are critical for managing MDR-TB and preventing further economic devastation.
Addressing these issues will be vital for achieving the WHO's end-TB strategy and ensuring sustainable healthcare solutions.

Related Results

Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract Introduction Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Perceptions of Telemedicine and Rural Healthcare Access in a Developing Country: A Case Study of Bayelsa State, Nigeria
Perceptions of Telemedicine and Rural Healthcare Access in a Developing Country: A Case Study of Bayelsa State, Nigeria
Abstract Introduction Telemedicine is the remote delivery of healthcare services using information and communication technologies and has gained global recognition as a solution to...
Assessment of Tuberculosis Drugs and Diagnostics in Katsina Central, Katsina State, Nigeria
Assessment of Tuberculosis Drugs and Diagnostics in Katsina Central, Katsina State, Nigeria
Study’s Novelty/Excerpt This study provides insights into the availability and inventory management of tuberculosis (TB) drugs and diagnostics in Katsina Central Senatorial Dist...
Gene Mutation Characteristics and Cluster Analysis of Multidrug-Resistant Mycobacterium Tuberculosis in Urumqi
Gene Mutation Characteristics and Cluster Analysis of Multidrug-Resistant Mycobacterium Tuberculosis in Urumqi
Abstract Objective To understand the molecular biological characteristics of multidrug-resistant Mycobacterium tuberculosis in Urumqi by the analysis of gene mutation and c...
Trends of Mycobacterium Tuberculosis and rifampicin resistance in Adigrat General Hospital, Eastern Zone of Tigrai, North Ethiopia
Trends of Mycobacterium Tuberculosis and rifampicin resistance in Adigrat General Hospital, Eastern Zone of Tigrai, North Ethiopia
Abstract Background: Tuberculosis is an infectious disease usually caused by Mycobacterium tuberculosis bacteria. The global emergence of mono- or multidrug-resistant tuber...

Back to Top